The global pharmaceutical landscape is undergoing a profound transformation in 2025, driven by US trade policies including tariffs and reshoring initiatives. This combined analysis, drawing extensively from the ODR India article on shifting sands in pharma industries, integrates insights on manufacturing capacity changes, investments, export revenues, imports, profitability impacts, and the specific role of API tariff exemptions.
It discusses Indian pharma acquisitions in the US, key investments by Indian firms, the shift of pharma manufacturing to the US, increases in US generic capacity, India’s kit-and-assemble model, largest generic producers, and service trade dynamics. The discussion covers generic and branded drugs from FY 2024-25 to partial FY 2025-26, with a focus on API exemptions and redirection of supplies.
Changes in US Generic and Branded Drugs Manufacturing Capacity: A Detailed Breakdown
From FY 2024-25 (ending March 31, 2025) to the partial FY 2025-26 (up to September 29, 2025), the US has witnessed a marked expansion in pharmaceutical manufacturing capacity, fueled by reshoring initiatives and tariffs. For generic drugs, which constitute about 90% of US prescriptions but only 20% of spending, capacity has increased by an estimated 15-20% year-over-year. This growth is largely attributable to a combination of foreign direct investments (FDI) and outward foreign direct investments (OFDI) from countries like India, alongside domestic expansions. Underutilised facilities, previously at 49% capacity, have been repurposed to add up to 30 billion doses annually without new construction. Key drivers include the May 2025 executive order linking US drug prices to international benchmarks and tariffs on APIs from China and India, prompting a shift away from foreign dependencies.
Approximately 60-70% of this generic capacity increase stems from monetary investments, including $50-100 billion in announced commitments from global firms like AstraZeneca ($50 billion by 2030 for chronic disease treatments), Johnson & Johnson ($55 billion for supply chain resilience), and Hikma Pharmaceuticals ($1 billion for R&D and expansion). The remaining 30-40% is due to manufacturing shifts, particularly from India and China, where companies are relocating operations to avoid tariffs as high as 245% on APIs. For instance, Indian firms have contributed $500-700 million in OFDI during partial FY 2025-26, focusing on acquisitions of US facilities for oncology and biologics generics.
For branded drugs, which represent less than 10% of prescriptions but over 80% of spending, capacity growth is estimated at 10-15%. The 100% tariff on branded and patented drugs, effective October 1, 2025, exempts firms building US plants, accelerating reshoring. About 70-80% of this increase is investment-driven, with companies like Eli Lilly and Novartis committing billions for API and biologic facilities. Shifts account for 20-30%, mainly from Ireland (which exported $50.3 billion in pharma to the US in 2024) and Switzerland, as firms localise production to evade tariffs. The US now produces APIs for 15% of branded prescriptions, up from lower levels pre-2025.
This dual-track expansion—generics focusing on volume and branded on high-value innovation—addresses 270 active drug shortages in early 2025, over 80% of which were generics.
Table Of Investments And Manufacturing Capabilities Shifting To The US
The following table compiles key investments and shifts from FY 2024-25 to partial FY 2025-26, based on announcements up to September 2025. Country shares reflect the proportion of total reshoring investments (estimated at $270 billion overall), with India at ~25-30% for generics, China ~10-15% (limited by tensions), Ireland ~20% for branded, and others like Germany and Switzerland ~15-20% each.
| Company/Country | Type (Investment/Shift) | Value (USD Million) | Date | Drug Type | Country Share (%) |
|---|---|---|---|---|---|
| Aurobindo Pharma (India) | Acquisition (Lannett for oncology/respiratory) | 250 | July 2025 | Generic | India: 25-30 |
| Syngene (Biocon, India) | Acquisition (Emergent facility for biologics) + Expansion | 36.5 + 13.5 | June/March 2025 | Generic/Branded | India: 25-30 |
| Sun Pharma (India) | Capex/Acquisition (Checkpoint for oncology) | 1,000-2,000 + 355 | Q2 2025 | Generic/Branded | India: 25-30 |
| Dr. Reddy’s (India) | Tie-Up (Oncology alliances) | 200-300 | Q2-Q3 2025 | Generic | India: 25-30 |
| Lupin (India) | Expansion (Repackaging hub) | 150-200 | Sep 2025 | Generic | India: 25-30 |
| Cipla (India) | Tie-Up (Third-party manufacturing) | 100-150 | Aug 2025 | Generic | India: 25-30 |
| Intas (India) | Acquisition (UDENYCA biosimilar) | 558 | Aug 2025 | Branded | India: 25-30 |
| Zydus Lifesciences (India) | Acquisition (Biologics facilities) | 75-141 | June 2025 | Generic/Branded | India: 25-30 |
| Jubilant Pharmova (India) | Expansion (PET network + Vaccine facility) | 50 + 285 | 2025 | Branded | India: 25-30 |
| AstraZeneca (UK/Sweden) | Investment (Virginia expansion) | 50,000 (by 2030) | 2025 | Generic/Branded | Others: 15-20 |
| Biogen (US/Ireland) | Expansion (North Carolina) | 2,000 | 2025 | Branded | Ireland: 20 |
| Novartis (Switzerland) | Infrastructure Investment | 23,000 (over 5 years) | April 2025 | Branded | Switzerland: 15-20 |
| Johnson & Johnson (US) | Production Boost | 55,000 | 2025 | Generic/Branded | US Domestic: 20-25 |
| Hikma (Jordan/China influence) | R&D/Manufacturing | 1,000 | 2025 | Generic | China: 10-15 |
Yearly percentage changes in investments and shifts show a surge: Pharma investments in the US rose ~4-fold in H1 FY 2024-25 compared to prior periods, with 2025 seeing a 50-60% increase over 2024 due to tariffs. Manufacturing shifts accelerated by 30-40% year-over-year, particularly for generics, as firms like Teva and Viatris boosted output by up to 57% at existing sites.
API Tariff Exemptions: Mechanisms, Conditions, And Implications
A critical facet of this reshoring involves tariff exemptions for Active Pharmaceutical Ingredients (APIs), the core chemical components of drugs. While explicit details on standalone API tariff exemptions are limited, exemptions are implicitly tied to broader US tariff policies. Generics, which heavily rely on APIs, are largely exempt from the 100% tariffs imposed on branded and patented drugs starting October 1, 2025, with transition periods of 1-2 years for firms building US capacity. For APIs specifically, the US has implemented tariffs of 25% on those sourced from China and 20% from India, covering essentials like antibiotics and antivirals. However, exemptions can be secured if companies establish US manufacturing hubs by the end of 2025, avoiding 50-100% tariffs on generics and potentially shielding API imports during the transition.
The functioning of these exemptions revolves around incentivising reshoring: firms must demonstrate investments in US facilities, such as acquisitions or expansions, to qualify. For instance, Indian companies are leveraging this by pouring $500-700 million in OFDI into US hubs in partial FY 2025-26, focusing on oncology and biologics (ODR investments: ). Conditions include compliance with US FDA standards and timelines for local production ramp-up, with exemptions acting as a bridge to reduce foreign dependencies. This policy, part of broader measures like the May 2025 executive order on drug pricing and the Biosecure Act, aims to cut US reliance on Chinese APIs, which control up to 90% of global supply.
Implications for India include safeguarded exports worth $20 billion annually, as firms like Aurobindo and Sun Pharma integrate US operations to bypass tariffs. For China, facing 20-245% tariffs (including 125% reciprocal and 20% fentanyl penalties), exemptions are harder to access due to geopolitical tensions, leading to retaliatory measures like 125% tariffs on US pharma and potential 10-20% export declines.
If India Reduces Chinese API Imports Due To US Shifts: Redirection Scenarios
India’s pharmaceutical sector is deeply intertwined with Chinese APIs, importing 70-85% of its needs under a “kit-and-assemble” model where assembly adds minimal value (13-17% GDP impact from manufacturing). As US reshoring progresses—with US generic capacity up 15-20% and branded 10-15% in 2025—Indian firms are shifting production stateside, potentially reducing Chinese API imports by 20-30% if US hubs fully operationalize.
This shift raises questions about the fate of displaced Chinese APIs, produced below market prices and poised for global dumping. Primary alternatives include:
(a) European Union (EU) Markets: With the EU’s Critical Medicines Act promoting diversification away from single suppliers, Chinese APIs could flood the region, absorbing 20-30% of redirected volumes. China’s expertise in intermediates for antibiotics and common meds positions it to capture EU share, especially as US barriers rise. This could lower EU drug costs but heighten dependency risks.
(b) Emerging Markets (Africa, Latin America, Southeast Asia): These regions, with growing demand for affordable generics, represent 30-40% potential uptake. China could pivot exports here, leveraging low prices to undercut local producers and expand influence, as seen in pre-2025 patterns where 80% of US generics were imported, partly via India.
(c) Domestic and Alternative Asian Markets: Within China, excess APIs might bolster internal production or be rerouted to allies like Russia or ASEAN nations, avoiding tariffs. India itself could still import selectively for non-US exports, but overall reductions would push 10-20% to these channels.
(d) Global Dumping and Supply Chain Adaptations: Chinese firms may relocate to low-tariff countries (e.g., Vietnam, Indonesia) for re-export, or face thin margins from overproduction. US tariffs on Chinese APIs could indirectly raise Indian costs by 5-10%, prompting further diversification, but creating opportunities for India to gain market share in non-China reliant segments.
In this scenario, Chinese API exports might decline 10-20% to India and the US combined, but recover through EU and emerging markets, potentially generating $10-15 billion in redirected revenues while pressuring global prices downward. For India, this fosters self-reliance but risks short-term supply disruptions; for China, it underscores the need for market pivots amid geopolitical strains.
Export Revenues And Profits From US-Based Manufacturing
Countries involved in reshoring—primarily India, China, Ireland, Switzerland, and Germany—could generate $100-150 billion in combined export revenues from US-manufactured drugs in 2025, up from $94 billion in total US pharma exports in 2024. India-linked firms might incur $20-30 billion (at ~Rs. 1,760-2,640 billion, with 1 USD = Rs. 88), China $10-15 billion, and Ireland/Switzerland $40-50 billion each. Profits from exporting US-produced drugs to global markets are projected at 15-25% margins, higher than offshore due to tariff exemptions and proximity to high-value markets like Europe. For instance, branded exports from US facilities could yield $3-5 billion in additional profits for Indian subsidiaries by supplying to emerging markets, offsetting domestic losses.
US-Manufactured Drugs Imported By India: Volumes And Projections
India imported approximately $1-2 billion worth of US-manufactured generic and branded drugs in FY 2024-25 to partial FY 2025-26, mainly branded specialties like oncology and biologics (e.g., 1-2% of India’s branded imports from the US). Generics account for ~30-40% of this, with branded the rest. Projections for the remaining FY 2025-26 suggest a 10-15% increase to $2.2-2.5 billion, driven by US tariffs raising global prices and India’s demand for advanced therapies. Future estimates (2026-2030) indicate growth to $5-7 billion annually if US reshoring stabilises supply, though India’s 70% API dependency on China could temper this.
Impact On Indian Companies’ Profitability And Stock Prices
The reshoring trend has pressured Indian pharma firms (excluding US subsidiaries), with profitability potentially declining 5-10% in FY 2025-26 due to reduced US exports. Companies like Sun Pharma face 8-10% earnings cuts in worst-case scenarios from tariffs on branded segments. However, diversification via US investments mitigates this, with overall sector margins holding at 15-20%. Stock prices on India’s BSE/NSE dipped 2-5% post-tariff announcements, with the pharma index falling 5.2% weekly. Firms like Cipla and Dr. Reddy’s saw sharper rebounds, as generics are largely spared, but long-term, reduced US reliance (down from 40-50%) could stabilise shares.
Percentage Of Indian Exports Impacted By US Domestic Production
If the US fully meets domestic needs, 30-40% of Indian pharma exports could be impacted, as the US accounts for 31-40% of India’s $25-30 billion annual exports (e.g., $9.8-10.5 billion in generics). With partial reshoring, 10-20% have already been or will be affected in 2025, prompting Indian firms to pivot to emerging markets and invest in US footholds for resilience.
In conclusion, while US reshoring enhances supply security through capacity expansions and API exemptions, it challenges export-dependent nations like India and China. Strategic investments and market pivots, as highlighted in ODR India analyses, offer pathways to adaptation, potentially reshaping global pharma dynamics for years to come.